AVITA Therapeutics, Inc. — Form 10-Q summary
Business context and reporting period. AVITA is a commercial-stage regenerative medicine company whose lead product is the RECELL System, FDA-approved in the U.S. for treating acute thermal burns in adults. The filing covers the quarter ended September 30, 2020, AVITA’s first quarter of fiscal 2021. The financial statements present quarterly results against the three months ended September 30, 2019. Some contents and statement headings refer to six months, so the period labels should be checked against the filed statements. The June 2020 redomiciliation from Australia to Delaware and related 1-for-100 implicit reverse split affect the presentation of shares and per-share data.
Key financial results
| Metric | Quarter ended Sep. 30, 2020 | Quarter ended Sep. 30, 2019 |
|---|---|---|
| Revenue | $5.06 million | $3.25 million |
| Gross profit / gross margin | $4.13 million / 82% | $2.63 million / 81% |
| BARDA income | $0.60 million | $2.05 million |
| Operating expenses | $14.94 million | $8.34 million |
| Operating loss | $(10.21) million | $(3.66) million |
| Net loss | $(10.23) million; $0.48 per share | $(3.57) million; $0.19 per share |
| Cash used in operations | $(7.71) million | $(4.88) million |
Revenue was primarily U.S. RECELL sales: $4.97 million, compared with $3.13 million a year earlier. Cash and restricted cash totaled $65.95 million at September 30, including $65.75 million of cash; cash declined by $7.89 million during the quarter. Current assets were $71.40 million and current liabilities $7.72 million. There was no significant external borrowing; balance-sheet obligations included $2.32 million of operating lease liabilities and a small finance lease balance. No dividends were paid, and the company said it had no plans to begin paying them.
Material changes and management commentary
- Revenue increased 56% year over year, while gross margin improved by about one percentage point.
- Operating expenses rose 79%. General and administrative expense increased 80%, including costs related to the NASDAQ/ASX cross-listing, one-time redomiciliation and SEC-filer costs, and severance. Research and development expense increased 96%, primarily reflecting pivotal trials for pediatric scalds, soft-tissue reconstruction, and vitiligo. Share-based compensation rose to $3.27 million from $0.67 million.
- BARDA income fell 71% as activities supporting the original FDA approval and related programs wound down. The company disclosed $9.6 million of remaining performance obligations, the majority associated with a July 2020 BARDA contract for RECELL systems for the Strategic National Stockpile over three years.
- Management expects operating expenses to increase as U.S. commercialization and clinical development expand, partly offset by increased RECELL sales. It expects to use cash reserves until product sales can fund operations; if additional capital cannot be raised when needed, it may have to reduce or scale back programs. No specific revenue, earnings, or cash-flow guidance was provided.
Outlook, risks, and unusual items
COVID-19 restricted hospital access, reduced opportunities to promote RECELL, affected burn-procedure volumes, and slowed clinical-study enrollment. Management also cited possible supply-chain disruption and said the pandemic’s future effects were uncertain. The filing says the quarter’s COVID-19 effects on operations, financial position, and cash flows were minor, while describing broader adverse impacts and uncertainty since the pandemic began. The company is not actively marketing RECELL internationally and reported no meaningful revenue from those markets.
Other items to note include the redomiciliation and reverse split, elevated noncash share-based compensation, and the decrease in BARDA income. The company reported no material outstanding or threatened litigation, and Item 1A stated no risk-factor changes in this filing. Management identified potential uncertainty in estimates, including receivable collectability and intangible-asset recoverability. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Important facts for investors to verify
- Confirm the reporting-period labels: the excerpt’s contents and some headings refer to six months, while the presented comparative results and MD&A describe the three months ended September 30.
- Track RECELL sales, U.S. procedure volumes, and the durability of the reported 82% gross margin, particularly as pandemic effects evolve.
- Assess cash burn against the $65.95 million cash-and-restricted-cash balance and management’s statement that future capital may be needed.
- Review the timing, conditions, and revenue recognition for the $9.6 million of remaining performance obligations, especially the BARDA stockpile contract.
- Monitor clinical-trial enrollment and progress toward expanded FDA approvals, as well as the impact of rising R&D spending and share-based compensation.